Aurora Investment Counsel Buys 1,211 Shares of Harmony Biosciences Holdings, Inc. $HRMY

Aurora Investment Counsel boosted its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMYFree Report) by 2.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,878 shares of the company’s stock after purchasing an additional 1,211 shares during the quarter. Aurora Investment Counsel owned about 0.11% of Harmony Biosciences worth $1,987,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in the stock. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Harmony Biosciences in the second quarter valued at about $698,000. Foster & Motley Inc. raised its stake in Harmony Biosciences by 139.5% in the second quarter. Foster & Motley Inc. now owns 25,290 shares of the company’s stock valued at $799,000 after buying an additional 14,731 shares during the last quarter. New York State Teachers Retirement System raised its stake in Harmony Biosciences by 1.6% in the second quarter. New York State Teachers Retirement System now owns 32,293 shares of the company’s stock valued at $1,020,000 after buying an additional 500 shares during the last quarter. Capital Management Corp VA raised its stake in Harmony Biosciences by 3.1% in the second quarter. Capital Management Corp VA now owns 352,566 shares of the company’s stock valued at $11,141,000 after buying an additional 10,605 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. purchased a new stake in Harmony Biosciences in the second quarter valued at about $600,000. Institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Stock Up 0.5%

Shares of HRMY stock opened at $26.02 on Tuesday. The company has a current ratio of 3.84, a quick ratio of 3.80 and a debt-to-equity ratio of 0.20. Harmony Biosciences Holdings, Inc. has a twelve month low of $25.52 and a twelve month high of $41.61. The stock has a 50 day moving average of $32.11 and a 200 day moving average of $32.64. The stock has a market cap of $1.50 billion, a P/E ratio of 8.39, a P/E/G ratio of 0.32 and a beta of 0.79.

Harmony Biosciences (NASDAQ:HRMYGet Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.68 EPS for the quarter, missing the consensus estimate of $0.78 by ($0.10). Harmony Biosciences had a net margin of 23.44% and a return on equity of 26.34%. The business had revenue of $200.49 million during the quarter, compared to analyst estimates of $204.37 million. During the same period in the previous year, the business posted $1.05 earnings per share. The firm’s revenue for the quarter was up 16.0% on a year-over-year basis. Harmony Biosciences has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Wall Street Analysts Forecast Growth

HRMY has been the subject of a number of research analyst reports. Truist Financial began coverage on Harmony Biosciences in a research note on Monday, July 21st. They issued a “buy” rating and a $48.00 price target for the company. Needham & Company LLC reduced their price objective on Harmony Biosciences from $48.00 to $41.00 and set a “buy” rating for the company in a research note on Wednesday, September 24th. The Goldman Sachs Group began coverage on Harmony Biosciences in a research note on Thursday, July 10th. They issued a “neutral” rating and a $33.00 price objective for the company. Weiss Ratings restated a “hold (c-)” rating on shares of Harmony Biosciences in a research note on Tuesday, October 14th. Finally, Deutsche Bank Aktiengesellschaft reduced their price objective on Harmony Biosciences from $54.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $45.56.

Get Our Latest Stock Report on Harmony Biosciences

About Harmony Biosciences

(Free Report)

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

See Also

Institutional Ownership by Quarter for Harmony Biosciences (NASDAQ:HRMY)

Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.